News

Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s full-year revenue guidance of $64.85 billion at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP profit of $1.72 per share was 2.4% above analysts’ consensus estimates.

Trump’s Pause on Trade Tariffs Gives Emerging Markets a Break

(Bloomberg) -- Emerging-markets assets gained on Tuesday after US President Donald Trump delayed new tariffs on goods from Mexico and Canada, and China delivered a relatively measured response to higher levies from the US.Most Read from BloombergState Farm Seeks Emergency California Rate Hike After FiresNew York’s First ‘Passive House’ School Is a Model of Downtown DensityWhen French Communists Went on a Brutalist Building BoomNYC’s Newest Transit Leader Builds a Worker-Driven StrategyHistoric L